Max Emmerich

A thought-provoking first @MANIFEST_CIRRP consortium meeting 🧠! 📈👩‍💻 Spotlighting emerging data/technologies across the consortium! 🧬🏥Highlighting the critical importance of cross-collaboration and harmonisation across consortium partners! Thank you to all in attendance!

Lovely day at our inaugural @MANIFEST_CIRRP consortium meeting, sharing our high dimensional PBMC profiling data in collaboration with IMU Biosciences. Excited to crack on with validating our findings and integrating them with other modalities across the platform!

An exciting opportunity to work on our multimodal datasets to interrogate the biology underlying immunotherapy response and toxicity!

From the March issue: Tracking Non-Genetic Evolution from Primary to Metastatic Clear Cell Renal Cell Carcinoma: #TRACERx Renal brnw.ch/21wRr47 By @Sanroman_Fern, @fendler_annika, @TurajlicLab, and colleagues @TheCrick @CNIOStopCancer @ChariteBerlin

It’s an honour to be standing for election as president of the @RCPhysicians I’ve been encouraged to stand by Members and Fellows who see the challenges we face and the disconnect between the College and its membership Thanks especially to my proposers: Prof Sir Richard…

🚨Ongoing opportunities to join the @MANIFEST_CIRRP platform 🚨 ➡️ Join a growing team of computational & cancer biologists 💊Immune-Oncology Biomarker Discovery 📍@TurajlicLab @TheCrick 🧑‍💻manifest-io.org.uk Link 👇

Delighted to share the @MANIFEST_CIRRP platform at #ESMOImmuno24 led by @TurajlicLab Builds on themes of 👨‍💻 Sample, assay & data harmonisation ➡️For generation of multi-modal/composite biomarkers 🚨Job opportunities across the platform! 👇 manifest-io.org.uk

Thrilled to get the first batch of samples from our @royalmarsdenNHS @TurajlicLab EXACT immunotherapy response study to our collaborators at IMU Biosciences as part of the @MANIFEST_CIRRP platform. Watch this space, exciting data to come! 👀🧪

An opportunity to shape our future We should replicate and spread good practice And importantly highlight poor practice if we have - inefficient systems (hyper rotation) - not enough motivated staff - the wrong staff - poor working conditions - lack of training numbers & more

Amazing achievement for @TurajlicLab and all collaborators. Really exciting opportunity to interrogate the biology of immunotherapy response, resistance, and toxicity.

We're looking for clinicians who are passionate about research to join our 3-year fully funded clinical PhD programme 🔬🩺 Projects are available with @ucl, @KingsCollegeLon and @imperialcollege 🗓️ Apply by 15 November 2024 crick.ac.uk/careers-study/…

Great opportunity via @TurajlicLab to work with @escardio to review pathophysiology of immune-related adverse events from cancer immunotherapy. Rising burden of cardio and other tox from IO. Significant need to work out targeted treatments to mitigate onlinelibrary.wiley.com/doi/10.1002/ej…

Excited to join this symposium and speak about our ongoing @TurajlicLab and @royalmarsdenNHS EXACT trial on immunotherapy toxicity. Do come along and hear about all the exciting Cancer Treatment Effects work across @RMresearch_